Zevra Therapeutics Inc

NASDAQ:ZVRA

Earnings Call Transcript 2024-Q1

[Operator]

Good morning, everyone. Thank you for joining the Zevra Therapeutics First Quarter 2024 Corporate Updates and Financial Results Call. Today's call is being recorded and will be made available on the company's website following the conclusion of the call. With that, I will now turn the call over to Nichol Ochsner, Vice President of Investor Relations and Corporate Communications at Zevra Therapeutics.

[Nichol Ochsner, executive]

Good morning, and thank you for joining us today to review Zevra Therapeutic's progress in the first quarter of 2024 outlining out clinical advances, operational achievements, and financial results.

Before we get started, let me take a moment to provide some important information. I encourage you to access the news release, which was published this morning and is available in the Investors section of Zevra's website.

As we begin our call, it's important to highlight that today's discussion will include forward-looking statements. Forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties, and other significant factors that may lead to actual results differing materially from the projections made. Please refer to the Risk Factors section in our most recent quarterly report on Form 10-Q and other filings with the SEC, and annual report on Form 10-K.

I am pleased to welcome Zevra's management team members participating in today's call. I'm joined today by Neil McFarlane, President and Chief Executive Officer; LaDuane Clifton, our Chief Financial Officer; Joshua Schafer, our Chief Commercial Officer and Executive Vice President of Business Development; Christal Mickle, our Chief Development Officer; and Adrian Quartel, our Chief Medical Officer. Now, I'll turn the call over to Neil.

[Neil McFarlane, executive]

Thank you, Nichol, and thank you all for making the time to join us today.

During the first quarter, we made steady progress in executing on our strategic objectives. On our last earnings call, we announced that we were focused on 3 key priorities: first, to successfully launch OLPRUVA and ensure access for patients; second, to prepare for the potential launch of arimoclomol; and third, to report the KP1077 program in sleep disorders. I'm pleased to report that we are executing on all of these objectives. And today, we'll share with you a summary of our key accomplishments in the first quarter and the reasons we are optimistic for 2024 and beyond.

In addition to executing on our 3 key priorities, we refinanced our existing debt with up to $100 million in committed capital, led by premier biotech investors, including Perceptive Advisors and HealthCare Royalty Partners. This new credit facility, which LaDuane will cover in more detail, has further strengthened our balance sheet and provides added capital flexibility to support our mission.

The company continues to work through a period of significant growth and transformation with the addition of talented people and capabilities from each of the 3 companies that have now come together to become one Zevra. The team is making significant progress advancing our rare disease portfolio. And in Q1, we initiated a long-range planning process, including a portfolio prioritization review, with a focus on building a sustainable business with reliable cash flows.

Achieving our strategic objectives to commercialize OLPRUVA and then, upon approval, successfully launching arimoclomol are key to reaching that seminal inflection point. We initiated the full commercial launch of OLPRUVA at the end of January 2024. As a reminder, OLPRUVA is indicated for the treatment of certain urea cycle disorders, or UCDs, which are a group of rare genetic disorders that can cause harmful levels of ammonia to build up in the blood, potentially resulting in neurocognitive impairments, brain damage and, in some cases, coma or death. We estimate that there are approximately 2,000 people in the U.S. with UCD, of which roughly half are diagnosed and treated. The UCD market in the U.S. is estimated at approximately $350 million annually.

Despite the availability of therapies, unmet needs of people living with UCD persist. We believe that OLPRUVA is well suited to address these needs as it provides personalized doses for each patient's requirements and is portable and easy for a patient to take. And most importantly, it is palatable, as it was formulated for overcoming the challenging taste and smell associated with other formulations of sodium phenylbutyrate.

Since launch, we've been focused on raising the awareness of OLPRUVA and demonstrating our commitment to UCD patients. In the quarter, we had 4 new patient enrollments, which we define as a prescription for a patient eligible for benefits investigation or our Quick Start program. We are encouraged by the progress that our rare disease specialists accomplished in the first few months of launch, meeting with more than 90% of the specialists at the 40 centers of excellence that treat people with UCD.

We've also assembled a team of marketers, patient services and market access professionals, as well as medical science leads and patient advocates, who are engaging with key stakeholders at patient events and medical conferences. Our managed care team has been working with government and commercial payers to ensure broad access for patients. We have seen meaningful growth in reimbursement coverage, which was 55% at the time we acquired OLPRUVA, to nearly 75% of covered lives as of May 1. Overall, I'm pleased with the progress we've made in the first few months of launch and look forward to reporting more details as the launch matures.

Zevra's commercial footprint was established to provide a high strategic fit between OLPRUVA and arimoclomol given that the majority of prescribers for both products work within the same centers of excellence. If arimoclomol is approved, we believe this close proximity and overlap in patient care will allow us to realize synergies and scale with our commercial infrastructure. In fact, our team has already begun to identify and compliantly engage with key opinion leaders and prescribers who treat UCD and Neimann-Pick disease type C, or NPC. Our market access team has initiated clinical discussions with payers requiring NPC and arimoclomol. These and other synergies across our brands will allow us to accelerate the launch of arimoclomol and ensure patients have access to this much-needed therapy.

As a reminder, arimoclomol is our investigational drug candidate in development for the treatment of NPC, a rare, genetic, progressive and potentially fatal neurologic disease. If approved, arimoclomol will be the first drug indicated for the treatment of NPC in the U.S.

Currently, there are approximately 900 people living with NPC, of which roughly 300 are diagnosed. Of those, approximately 70 are enrolled in our expanded access program, or EAP. During the quarter, the FDA assigned a new PDUFA date of September 21, 2024 and we look forward to [indiscernible] to present the resubmission for discussion at an Advisory Committee meeting for which we are thoroughly preparing.

The National Neimann-Pick Disease Foundation, known as NNPDF, spearheaded efforts with 6 other advocacy and research organizations to compile a petition of nearly 1,000 signatures from NPC patients, caregivers and physicians with direct experience utilizing arimoclomol and it was submitted to the FDA in Q1. We are overwhelmed by the outpouring of support for arimoclomol within the community. As the FDA review continues, we will maintain our EAP and continue working tirelessly to bring this potential therapy to patients living with this devastating rare disease.

We continue to work closely with key opinion leaders to educate on arimoclomol's disease-modifying clinical profile and raise awareness of the heterogeneous presentation of NPC. In April of 2024, we presented new long-term, real-world data to the Society for Inherited Metabolic Disorders. The presentation included data from EAP patients from the U.S. centers and it demonstrated that adults treated with arimoclomol, including those with and without miglustat use, had a stable disease course, which is defined as not showing disease progression over the 2 years of treatment. The safety profile was consistent with that observed in the Phase II/III study. If approved, we intend to utilize our clinical data, as well as emerging real-world evidence from our EAP, to establish arimoclomol as foundational treatment for people living with NPC.

Now I'd like to turn your attention to KP1077, our clinical candidate being developed as a treatment for idiopathic hypersomnia, or IH, a rare, chronic sleep disorder. IH is characterized by excessive daytime sleepiness with uncontrollable need to sleep and difficulty waking. There remains an unmet need and we estimate that 37,000 people in the U.S. are currently diagnosed with IH. As you may recall, KP1077, serdexmethylphenidate, or SDX, was designed to steadily release d-methylphenidate, its active ingredient. This unique pharmacokinetic profile allows for flexible dosing to overcome these primary IH symptoms. This profile ensures that patients receive the optimal drug concentration in waking and active hours. SDX is currently designated as a Schedule IV controlled substance by the U.S. Drug Enforcement Administration.

During the quarter, we reported top line data from our Phase II study of KP1077 in patients with IH. We are encouraged by the results, which showed that KP1077 is well tolerated and demonstrates early signs of differentiated and clinically meaningful benefits. The study successfully fulfilled the objectives of informing the design of a pivotal efficacy trial, and we are planning an end-of-Phase II meeting with the FDA in Q3. Since completing the trial and reporting top line results in March, we've been working closely with the sleep community to interpret these results. With only one approved treatment, there remains a large unmet need for therapies with different mechanisms of action to address the symptoms of IH. We look forward to presenting the full data package from our completed study at the upcoming Sleep 2024 Conference in early June.

As part of the strategic planning initiative kicked off in January, we completed our preliminary evaluation of the Celiprolol program for the treatment of Vascular Ehlers-Danlos Syndrome, or VEDS, which impairs [ coll 381 ] connective tissue and leads to vascular and hollow organ ruptures. Celiprolol's mechanism of action is designed to reduce the mechanical stress on collagen fibers within the arterial wall through vascular dilation and smooth muscle relaxation. Celiprolol received orphan drug and breakthrough therapy designations from the FDA. The Phase III protocol is being conducted under a Special Protocol Assessment, or SPA, agreement with the FDA.

We recently [ restarted ] recruitment for the Phase II, also known as the DiSCOVER trial, to support patients currently enrolled and to preserve the value of the program while we complete our portfolio review. This is a decentralized event trial designed with Celiprolol on VEDS-related event reduction. Celiprolol is a primary treatment option in various European countries, and we believe that it could address a significant unmet need in the U.S. as there are no approved treatments for the 7,500 diagnosed patients with VEDS.

Looking ahead, we have 3 areas of focus: first, continue to drive the launch of OLPRUVA; second, to prepare for a potential outcome and launch of arimoclomol; and third, to advance KP1077.

Now I'll hand the call over to LaDuane, who will provide an update on our financial results.

[R. Clifton, executive]

Thank you, and good morning. Before I begin, I would encourage you to refer to our quarterly report on Form 10-Q, which we intend to file Thursday, post-market, for more detailed information.

As Neil has already outlined, first quarter was a time of solid execution as we drive the business towards the accomplishment of our strategic objectives. Our financial results for the first quarter reflect our foundation of financial strength as we continued our investments in building out our commercial capabilities and in the advancement of our development programs.

Net revenue for the quarter was $3.4 million, which includes $2.2 million of net reimbursements from the French EAP for arimoclomol and $1.2 million of royalty and other reimbursements under the AZSTARYS license. Currently, we recognize commercial product revenue when shipments are received by our specialty pharmacy. Based on the early days of launch and inventory in the channel, OLPRUVA sales were de minimis during the quarter.

R&D expenses for the first quarter increased to $12.3 million, which was primarily driven by the KP1077 Phase II trial in IH that has since been completed, as well as our work to support the arimoclomol NDA during the ongoing review cycle and to prepare for a potential outcome sometime prior to the upcoming PDUFA date.

Selling, general and administrative expenses were $9.9 million and reflect an increase in personnel costs and professional fees associated with our commercial infrastructure.

Net loss for Q1 2024 was $16.6 million, or $0.40 per basic and diluted share.

As of March 31, 2024, total cash, cash equivalents and securities were $52.7 million, which was a decrease of $15 million compared to December 31, 2023.

Total shares of common stock outstanding were 41.8 million and fully diluted shares outstanding decreased by 1.4 million to 56.8 million, which includes approximately 5.6 million shares issuable upon exercise of warrants.

As Neil mentioned, on April 10, we announced the refinancing of our existing debt with a new credit facility which provides up to $100 million in committed capital. With the initial draw of $60 million, we have refinanced our existing debt of approximately $43 million and added an incremental $14 million in net cash proceeds to the balance sheet after fees and discounts. A second tranche of up to $20 million is available until October 5, 2025 and a third tranche of up to $20 million will become available upon approval of arimoclomol, in each case, subject to certain terms and conditions.

By restructuring the amounts previously outstanding on 2 different facilities, we have simplified and extended the maturity while also providing additional nondilutive capital to support our mission. As a result of this transaction and based on our current operating plan, available cash, cash equivalents and investments are expected to extend our cash runway further into 2026, subject to continuing compliance with our debt covenants.

Our forecast includes commercial revenue from sales of OLPRUVA, reimbursement from the French EAP for arimoclomol and ongoing royalties under the AZSTARYS license agreement. It does not include commercial revenue from the sales of arimoclomol nor the sale of the priority review voucher, which would follow an FDA approval. Disciplined utilization of resources will continue to be our guiding principle as we make prudent investments in our commercial and development operations while matching those investments to our operating requirements.

We are optimistic about the opportunities we have in store during 2024. Our focus is on creating long-term value for shareholders by executing against our plan in support of our mission to become a leading rare disease company.

We will now turn the call over to the operator for questions.

[Operator]

[Operator Instructions] We'll take our first question from Tim Lugo with William Blair.

[Tim Lugo, analyst]

For arimoclomol, I know the data submitted to the Agency included use of arimoclomol alone and in combination with miglustat. Can you just clarify how you expect the product to eventually be used by patients in combination going to be more -- used more? Is it going to be used alone more? Just what do you view the strength of data for both of those approaches?

[Neil McFarlane, executive]

Tim, thanks for that question. So in clinical trials, that was performed [indiscernible] patients that were both on miglustat and [ notomegostat ]. And what we found is that patients, whether they were on miglustat or [ notomegostat ], improved whilst on arimoclomol.

What we saw overall is that there was not a big difference between the improvement in patients with miglustat or without miglustat. So we believe that, as we go to market, that arimoclomol will be the foundational therapy. It is a disease modifying treatment. And whether physicians and patients want to add on miglustat to that foundational therapy is really up to them. I think it needs to be noted that miglustat is not approved for treatment of NPC and arimoclomol will most likely be the only approved foundational therapy for patients with NPC.

[Tim Lugo, analyst]

And can you discuss -- it sounds like the patient advocacy groups are, I guess, kind of rallying around the filing a bit. Can you maybe summarize your interactions with those groups or some of the patient advocacy you've heard in the past quarter? It seems like it's really ramping into the -- I guess after the submission.

[Joshua Schafer, executive]

Tim, this is Josh Schafer. And we have been very engaged with the patient advocacy community for several years now. And they have demonstrated their support of arimoclomol, most recently signing a petition with 1,000 signatures of patients, caregivers and physicians who are in support of arimoclomol submission and eventual and hopeful approval. So that certainly demonstrates their support for arimoclomol and for Zevra.

And we remain very committed to that patient community. It's a very well-organized community. They have helped to build a lot of the awareness for arimoclomol that we hope will help with the launch and approval. And as you know, there are about 70 patients in our expanded-access program in the United States, plus another approximately 300 patients in the U.S. that are actively being treated. And we hope to be able to make arimoclomol available for all of those patients.

[Tim Lugo, analyst]

And I guess one last question. I believe you mentioned 300 NPC patients were diagnosed, but there was the expectation of 900 here in the U.S. Can you just talk about that difference in the differential between diagnosed and expectation?

[Neil McFarlane, executive]

Sure. The 900 is the estimated prevalence of the disease. Not all of those patients are confirmed diagnosis. That is based on some claims data that was published in 2021, I believe. And of those 900, there are about 350 who have been diagnosed and are receiving some form of treatment, whether that's miglustat today or treatment for symptomatic disease.

[Operator]

We will take our next question from Jonathan Aschoff with ROTH MKM.

[Jonathan Aschoff, analyst]

I was curious if you might be able to help us out a little with de minimis OLPRUVA revenue. Any help there, or you just wish to keep that quiet for now?

[Neil McFarlane, executive]

It's really a function of sort of the product that's already at the specialty pharmacies. And therefore, we had modest shipments during Q1. So our main focus during Q1 has been to build awareness, to get out and make contact with the key opinion leaders and prescribing physicians. And we've touched actually over 90% of those folks at this point. So in future quarters, as enrollments continue to build, we'll see more pulls into the pharmacy and, therefore, revenue will go up, but de minimis is de minimis.

[Jonathan Aschoff, analyst]

How about time to celiprolol data, if you can venture a guess there at all or maybe help us out with the enrollment percentage at present [indiscernible] will give us a sense of at least when the data will come? I know it's several years.

[Unknown Executive]

Yes, Jonathan, thank you for that question. So we started recruitment to support the patients that are currently enrolled. We're looking at celiprolol as part of our whole portfolio, as part of [Technical Difficulty] we understand the value in the programs when we started this program. As I said, this is running on a SPA agreement with the FDA, and we're looking at 40 [indiscernible]. We currently have 17 patients enrolled, and we continue to evolve throughout the rest of the year.

[Jonathan Aschoff, analyst]

Okay. And also, have you noticed anything on the part of Amgen regarding marketing strategy with RAVICTI? Or is it just absolutely not a needle mover for them?

[Neil McFarlane, executive]

So we can't really comment on what Amgen is doing, but we know that there are roughly 800 patients today that are receiving some therapy for UCD, and about 25% of those patients still have some hyperammonemic events. And that's probably due to poor compliance as a result of patients not being able to tolerate current therapies. We believe that OLPRUVA is going to help solve that problem with this ability to be personalized in its dose, to be portable, in the way that it's delivered and, most importantly, the palatability that we think will lead to better outcomes for these patients.

[Jonathan Aschoff, analyst]

And lastly, just a weird little detail. On your 10-K, it says, on 3/30, you had 43.4 million shares. Then a day later, in this press release here today, it says you have 41.8 million. So did you buy back 1.6 million, or what happened?

[Neil McFarlane, executive]

There was no repurchasing during Q1. And so shares outstanding as of end of the year was 41.5 million and shares outstanding as of 3/31, it's 41.8 million. So are you referring to the fully diluted share count, Jonathan?

[Jonathan Aschoff, analyst]

It's just whatever is on Page 1 of the 10-K. I might have to look at this number.

[Neil McFarlane, executive]

Okay.

[Jonathan Aschoff, analyst]

[indiscernible]

[Neil McFarlane, executive]

Yes.

[Jonathan Aschoff, analyst]

[indiscernible] just a little more detail.

[Neil McFarlane, executive]

Yes. I'm not sure. The shares outstanding when you see the 10-Q tomorrow will be 41.8 million.

[Operator]

[Operator Instructions] We'll go next to Louise Chen with Cantor.

[Louise Chen, analyst]

Congrats on all the progress this quarter. So I wanted to ask you, on peak sales for OLPRUVA, how do you think about that? And how long do you think it will take you to get there?

And then another question we get a lot is just on KP1077, comparing it and kind of contrasting it to other products in the market and where your competitive advantage is?

And then lastly, just on your new opportunities here with the celiprolol product, what is the market opportunity? And how do you think about it? And what makes you excited about this opportunity?

[Joshua Schafer, executive]

Sure. This is Josh, and I'll address the OLPRUVA question. So as we noted, the first quarter was really focused on building awareness of the drug. We have been really pleased with the performance of the team.

I'd like to remind you that, in the first quarter, we built an entire commercial organization of really talented and experienced rare disease experts who've been out talking with the specialists. They've been able to engage with about 90% of prescribers. Also, importantly, we've been engaged with the patient advocacy groups and the payer community, and we now have 75% of covered lives. So all of that really bodes well for what we think will be some momentum as we build into the launch.

It's also important to note that these patients, like many rare disease patients, really only go to see their physicians every 6 to 9 months. So we're pleased with the progress that we're seeing now, but we've got more to do. And we're not -- yes, I'll leave it at that.

[Neil McFarlane, executive]

I'll ask Adrian to see if he can talk a little bit about the KP1077 differentiation.

[Adrian Quartel, executive]

Yes. Thanks for the question. So obviously [indiscernible] actually a fairly large patient population [indiscernible] so we're talking about 37,000 patients. There's still a significant unmet medical need in that large modulation. We believe that KP1077 provides a unique mode of action addressing specific symptoms of idiopathic hypersomnia. So we believe we have a differentiated product, specifically when it comes to its PK profile [indiscernible] it's scheduled for [indiscernible] safety. So we believe that it [indiscernible] the space with the idiopathic hypersomnia population.

[Neil McFarlane, executive]

I think you also asked a little bit about the celiprolol market opportunity, if I understood it, as well.

[Unknown Executive]

Yes, celiprolol is used for the treatment of VEDS, of which there are about 7,500 patients in the U.S. In some European countries, it is currently being used as the standard of care for those patients. But other than that, there really is no treatment option for these patients other than surgery. So we think that, if approved, celiprolol would really offer some benefit for these patients who have no other available therapies.

[Operator]

[Operator Instructions] We'll go next to Oren Livnat with H.C. Wainwright.

[Oren Livnat, analyst]

I just want to follow up on OLPRUVA. So I know it's very early and you've only had 4 patients enrolled that you've called out here. But can you talk about where those patients come from? Are those de novo patients or switchers from a less palatable product? And what experience are you having very early on here with trying to adjudicate, to reimburse therapy with these initial patients? Are you getting any pushback regarding February pricing, relative pricing? And how fast do you think you can convert these and then hopefully future enrolled patients to paid therapy?

[Joshua Schafer, executive]

First of all, it's important to note that the 4 patients that we reported were just those new enrollments for the quarter. There are more than that currently on OLPRUVA or who have been prescribed to OLPRUVA. And these patients are coming from a variety of different places. Either they're switches from current therapy. We also do have some patients who are new to therapy and have not received any treatment.

Like all rare disease products, there are step-throughs and step-edits that take place in order for patients to receive treatments for their rare diseases. But we've been really pleased with the progress that we're getting from our reimbursement in covered lives. You get 75% covered lives -- again, reflecting back when we closed the transaction, it was at 55%. So we've made great progress there. So I think we feel like we're in a good place right now and on par to be able to compete with [ Severin ] and [ Ubithy ].

[Oren Livnat, analyst]

And if I could just follow up on what you said there, can you help us understand, I guess, how many patients were already on therapy? Was that under the prior Acer launch? And are those paid subjects, or are they getting free drug now and you're hoping to convert them to therapy? Or is the reason that revenue is de minimis is just that they are paid therapy patients now, but they're just already from before your time, so to speak? There was already enough supply in the channel such that you didn't need to shift?

[Joshua Schafer, executive]

Yes. So it's a little -- it's kind of a combination of all the things that you just offered there. There were a handful of patients who have received OLPRUVA and were enrolled prior to the close of the transaction. However, most of them came in late in 2023, into the first quarter, and now into the second quarter. And again, they're coming from a variety of different sources, whether those are switches or naive.

And those -- and sorry, I was just thinking about the rest of your question there. And those are a combination of both paid patients as well as those who have gone on to our Quick Start program, which allows us to get patients onto therapy while we're investigating the benefits and attempting to convert them to paid patients as well.

[Oren Livnat, analyst]

All right. I think I'll follow up you guys afterwards. Yes. Go ahead.

[Joshua Schafer, executive]

I think there was a third part to your question, which was really around the de minimis revenue. And that -- it's important to note that there is a disconnect, as I mentioned, between the revenue recognition and the enrollments due to the way that we still [indiscernible] into our specialty pharmacy. So that is kind of a reflection of just that dynamic.

[Oren Livnat, analyst]

All right. And are you hearing anything regarding relative pricing of these drugs? Or are they all expensive enough and presumably some unmet need with these patients if they're even considering your product that it's not an issue, the potentially slightly cheaper nature of a competing product?

[Joshua Schafer, executive]

Yes. So as you probably know, we've seen a lot of payers begin to put RAVICTI on its exclusion list as a result of RAVICTI's high price. We are benefiting from that, given that we have a significantly less -- a lower cost, but more importantly, that we are able to compete on the clinical benefits of OLPRUVA. And so that dynamic is certainly helping us.

[Operator]

We will take our next question from Sumant Kulkarni with Canaccord Genuity.

[Sumant Kulkarni, analyst]

[indiscernible] so 2 questions. On arimoclomol, can you compare and contrast your approach with [ intra-bio ] and the potential for you to have an [indiscernible] that is [indiscernible] given the proximity of the 2 action dates?

And the second question is, have you had [indiscernible] marketable and what are potential findings and those that might have considered -- you guys have considered surprising or counterintuitive?

[Neil McFarlane, executive]

I'll take the last question, and I'll hand off the question to Adrian around differentiation. To answer your question, yes, we are thoroughly preparing for a potential advisory committee. We've had a number of Red Team/Blue Team exercises, preparing briefing books with multiple ad -- mock [ adcoms ] coming that we're learning from and perfecting our craft as we move forward. So I feel like we are thoroughly preparing for that at this point.

[Adrian Quartel, executive]

In regards to the 2 products being tested for [indiscernible] in clinical patients, I think we have started that. I think it's important to understand that arimoclomol with [ any ] mode of action is really disease-modifying [indiscernible] where the [indiscernible] product is more symptomatic treatment of [ advancing ] symptoms. The differentiated mode of action and specific clinical profile of arimoclomol, we believe, will lead to be the foundational treatment for patients with NPC, and that's kind of what we're looking forward to.

[Operator]

And this concludes the Q&A portion of today's call. I would now like to turn the call back over to Neil McFarlane for any additional and closing remarks.

[Neil McFarlane, executive]

Thank you, Ashley. We continue to make solid advances towards achieving our mission of building a leading patient-focused rare disease therapeutic company. As we look to our catalysts in the second half of 2024, our strategic priorities are clear, and we look forward to updating you in the future. Thanks for joining us today. Have a wonderful day.

[Operator]

Thank you. This does conclude today's program. You may disconnect at any time and...